Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus

Therapeutic Advances in Endocrinology and Metabolism

Volumn 6, Issue 1, 2015, Pages 3-18

  Harris, Kira B ^a   McCarty, Delilah J ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

albiglutide; exenatide; exenatide long acting release; GLP 1 RAs; liraglutide; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBIGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; SULFONYLUREA;

BODY WEIGHT; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SINUSITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 84922816507     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018814558242     Document Type: Review

References (88)

1. Ahren B. Johnson S. Stewart M. Cirkel D. Yang F. Perry C. et al. (2014) HARMONY 3: 104-week randomized, double-blind, placebo- and active- controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 37: 2141–2148.
2. Amylin Pharmaceuticals, Inc. (2011) Byetta (exenatide) package insert. Available at: http://documents.byetta.com/Byetta_PI.pdf> (accessed 12 July 2014).
3. Amylin Pharmaceuticals, Inc. (2012) Bydureon (exenatide extended release) package insert. Available at: http://documents.bydureon.com/Bydureon_PI.pdf> (accessed 12 July 2014).
4. Apovian C. Bergenstal R. Cuddigy R. Qu Y. Lenox S. Lewis M. et al. (2010) Effects of exenatide combined with lifestyle modicfications in patients with type 2 diabetes. Am J Med 123: e9–17.
5. Barnett A. Burger J. Johns D. Brodows R. Kendall D. Roberts A. et al. (2007) Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 29: 2333–2348.
6. Belvins T. Pullman J. Malloy J. Yan P. Taylor K. Schulteis C. (2011) DURATION:5 Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 96: 1301–1310.
7. Bergenstal R. Forti A. Chiasson J. Wolochak M. Boldrin M. Balena R. (2012) Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-Emerge 4 trial). Diabetes Ther 3: 13.
8. Bergenstal R. Lewin A. Bailey T. Chang D. Roberts V. (2009) Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 25:65–75.
9. Bergenstal R. Wysham C. MacConell L. Malloy J. Walsh B. Yan P. et al. (2010) Efficacy and safety of exenatide once weekly versus sitaglipitin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet 376: 431–439.
10. Blonde L. Klein E. Han J. Zhang B. Mac S. Poon T. et al. (2006) Interim analysis of the effects of exenatide treatment on A1c, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8: 436–447.
11. Bolli G. Munteanu M. Dotsenko S. Neimoeller E. Boka G. Wu Y. et al. (2014) Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabetes Med 31: 176–184.
12. Bunck M. Cornner A. Eliasson B. Heine R. Shaginian R. Taskinen M. et al. (2011) Effects of exenatide on measure of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 34: 2041–2047.
13. Buse J. Drucker D. Taylor K. Kim T. Walsh B. Hu H. et al. (2010) DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33: 1255–1261.
14. Buse J. Bergenstal R. Glass L. Heilmann C. Lewis M. Kwan A. et al. (2011) Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154: 103–112.
15. Buse J. Henry R. Han J. Kim D. Fineman M. Baron A. (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628–2635.
16. Buse J. Klonoff D. Nielsen L. Guan X. Bowlus C. Holcombe J. et al. (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29: 139–153.
17. Buse J. Rosenstock J. Sesti G. Schmidt W. Montanya E. Brett J. et al. (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39–47.
18. Buse J. Nauck M. Forst T. Sheu W. Shenouda S. Heilmann C. et al. (2013) Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomized, open-label study. Lancet 381: 117–124.
19. Charbonnel B. Steinberg H. Eymard E. Xu L. Thakkar P. Prabhu V. et al. (2013) Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia 56: 1503–1511.
20. Chiquette E. Toth P. Ramirez G. Cobble M. Chilton R. (2012) Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag 8: 621–629.
21. Davies M. Donnelly R. Barnett A. Jones S. Nicolay C. Kilcoyne A. (2009) Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the helping evaluate exenatide in patients with diabetes compared with long-acting insulin (HEELA) study. Diabetes Obes Metab 11: 1153–1162.
22. Davies M. Heller S. Sreenan S. Sapin H. Adetunji O. Tahbaz A. et al. (2013) Once-weekly exenatide versus once- or twice- daily insulin detemir. Diabetes Care: 36: 1368–1376.
23. de Fronzo R. Ratner R. Han J. Kim D. Fineman M. Baron A. (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092–1100.
24. Derosa G. Franzetti I. Querci F. Carbone A. Ciccarelli L. Piccinni M. et al. (2012) Exenatide plus metformin compared with metformin alone on β-cell function in patients with type 2 diabetes. Diabet Med 29: 1515–1523.
25. Derosa G. Franzetti I. Querci F. Carbone A. Ciccarelli L. Piccinni M. et al. (2013) Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial. Pharmacotherapy 33: 817–826.
26. Derosa G. Maffioli P. Salvadeo S. Ferrari I. Ragonesi P. Querci F. et al. (2010) Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 12: 233–240.
27. Derosa G. Putignano P. Bossi A. Bonaventura A. Querci F. Franzetti I. et al. (2011) Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 666: 251–256.
28. de Vries J. Bain S. Rodbard H. Seufert J. D'Alessio D. Thomsen A. et al. (2012) Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1c targets. Diabetes Care 35: 1446–1454.
29. Diamant M. Gaal L. Stranks S. Guerci B. MacConell L. Haber H. et al. (2012) Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 35: 683–689.
30. Diamant M. Gaal L. Stranks S. Northrup J. Cao D. Taylor K. et al. (2010) Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (Duration-3): an open-label randomized trial. Lancet 375: 2234–2243.
31. Drucker D. Buse J. Taylor K. Kendall D. Trautmann M. Zhuang D. et al. (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 372: 1240–1250.
32. Frias J. Edelman S. (2007) Incretins and their role in the management of diabetes. Curr Opin Endocrinol Diabetes Obes 14: 269–276.
33. Gallwitz B. Bohmer M. Segiet T. Molle A. Milek K. Becker B. et al. (2011) Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care 34:604–606.
34. Gallwitz B. Guzman F. Dotta F. Guerci B. Simo R. Basson B. et al. (2012) Exenatide twice daily versus glimepiride for prevent of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomized controlled trials. Lancet 379: 2270–2278.
35. Gao Y. Yoon K. Chuan L. Mohan V. Ning G. Shah S. et al. (2009) Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 83: 69–76.
36. Garber A. Henry R. Ratner R. Garcia-Hernandez P. Rodriquez-Pattzi H. Olvera-Alvarez I. et al. (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52 week, phase III, double-blind, parallel-treatment trial. Lancet 373: 473–481.
37. Garber A. Henry R. Ratner R. Hale P. Chang C. Bode B. et al. (2011) Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provide sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 13: 348–356.
38. Gill A. Hoogwerf B. Burger J. Bruce S. MacConell L. Yan P. et al. (2010) Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 9: 1–7.
39. GlaxoSmithKline L.L.C. (2014) Tanzeum (albiglutide) package insert. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/literabel/2014/125431s000lbl.pdf (accessed 12 July 2014).
40. Heine R. van Gaal L. Johns D. Mihm M. Widel M. Brodows R. (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes; a randomized trial. Ann Intern Med 143: 559–569.
41. Holst J. (2006) Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49: 253–260.
42. Holst J. (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409–1439.
43. Inzucchi S. Bergenstal R. Buse J. Diamant M. Ferrannini E. Nauck M. et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364–1379.
44. Ji L. Onishi Y. Ahn C. Agarwal P. Chou C. Haber H. et al. (2013) Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Invest 4: 53–61.
45. Kadowaki T. Namba M. Yamamura A. Sowa H. Wolka A. Brodows R. (2009) Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocrine J 56: 415–424.
46. Kendall D. Riddle M. Rosenstock J. Zhuang D. Kim D. Fineman M. et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083–1091.
47. Klonoff D. Buse J. Nielsen L. Guan X. Bowlus C. Holcombe J. et al. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type diabetes treated for at least 3 years. Curr Med Res Opin 24: 275–286.
48. Kreymann B. Ghatei M. Williams G. Bloom S. (1987) Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet 2: 1300–1304.
49. Levin P. Mersey J. Zhou S. Bromberger L. (2012) Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract 18: 17–25.
50. Lilly (2013) Lilly's investigational GLP-1 receptor agonist, dulaglutide, showed superior glycemic control versus comparators in patients with type 2 diabetes: safety and efficacy results from three phase III registration clinical trials presented at the 73td American diabetes association scientific sessions. Available at: http://lilly.mediaroom.com/index.php?s=9042&item=137218%20 (accessed 15 July 2014).
51. Liutkus J. Rosas Guzman J. Norwood P. Pop L. Northrup J. Cao D. et al. (2010) A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes Metab 12: 1058–1065.
52. Lu C. Wu T. Shih K. Ni E. Reed V. Yu M. et al. (2013) Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus. J Formos Med Assoc 112: 144–150.
53. MacConell L. Pencek R. Li Y. Maggs D. Porter L. (2013) Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes 6: 31–41.
54. Marbury T. Flint A. Segel S. Lindegaard M. Lasseter K. (2014) Poster 1010 presented at: 74th American Diabetes Association Scientific Sessions; 13–17 June 2014; San Francisco, CA.
55. Marre M. Shaw J. Brandle M. Bebakar W. Kamaruddin N. Strand J. et al. (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26: 268–278.
56. Moretto T. Milton D. Ridge T. MacConell L. Okerson T. Wolka A. et al. (2008) Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 230: 1448–1460.
57. Nauck M. Baller B. Meier J. (2004) Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53: S190–S196.
58. Nauck M. Duran S. Kim D. Johns D. Northup J. Festa A. et al. (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50: 529–267.
59. Nauck M. Frid A. Hermansen K. Shah N. Tankova T. Mitha I. et al. (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 32: 84–90.
60. Nauck M. Horton E. Andjelkovic M. Ampudia-Blasco F. Parusel C. Boldrin M. et al. (2013) Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with type 2 diabetes: an open-label randomized trial. Diabet Med 30: 109–113.
61. Nauck M. Kleine N. Orskov C. Holst J. Willms B. Creutzfeldt W. (1993) Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741–744.
62. Nauck M. Petrie J. Sesti G. Mannucci E. Courreges J. Atkin S. et al. (2012) The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes. Diabetologia 55(Suppl. 1): abstract 2-OR.
63. Nauck M. Stockmann F. Ebert R. Creutzfeldt W. (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29: 46–52.
64. Novo Nordisk A/S (2013) Victoza (liraglutide) package insert. Available at: http://www.novo-pi.com/victoza.pdf (accessed 12 July 2014).
65. Onishi Y. Koshiyama H. Imaoka T. Haber H. Scism-Bacon J. Boardman M. (2013) Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest 4: 182–189.
66. Pratley R. Nauck M. Bailey T. Montanya E. Cuddihy R. Filetti S. et al. (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomized, parallel-group, open-label trial. Lancet 375: 1447–1456.
67. Pratley R. Nauck M. Bailey T. Montanya E. Cuddihy R. Filetti S. et al. (2011) One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 65: 397–407.
68. Pratley R. Nauck M. Bailey T. Montanya E. Filetti S. Garber A. et al. (2012) Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 35: 1986–1993.
69. Pratley R. Nauck M. Barnett A. Feinglos M. Ovalle F. Harman-Boehm I. et al. (2014) Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomized, open-label, multicenter, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2: 289–297.
70. Pratley R. Urosevic D. Boldrin M. Balena R. (2013) Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6). Diabetes Obesity Metabolism 15: 234–240.
71. Ratner R. Maggs D. Nielsen L. Stonehouse H. Poon T. Zhang B. et al. (2006) Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 8: 419–428.
72. Riddle M. Henry R. Poon T. Zhang B. Mac S. Holcombe J. et al. (2006) Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 22: 483–491.
73. Rosenstock J. Balas B. Charbonnel B. Bolli G. Boldrin M. Ratner R. et al. (2013 a) The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes. Diabetes Care 36: 498–504.
74. Rosenstock J. Hanefeld M. Shamanna P. Min K. Boka G. Miossec P. et al. (2014) Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complications 28: 386–392.
75. Rosenstock J. Rodbard H. Bain S. D'Alessio D. Seufert J. Thomsen A. et al. (2013 b) One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. J Diabetes Complications 27: 492–500.
76. Russell-Jones D. Cuddihy R. Hanefeld M. Kumar A. Gonzalez J. Chan M. et al. (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4). Diabetes Care 35: 252–258.
77. Russell-Jones D. Vaag A. Schmitz O. Sethi B. Lalic N. Antic S. et al. (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52: 2046–2055.
78. Sanofi (2013) Sanofi provides update on lixisenatide new drug application in US Available at: http://m-en.sanofi.com/Images/33756_20130912_lixisenatide_en.pdf (accessed 8 July 2014).
79. Sathyanarayana P. Jogi M. Muthupillai R. Krishnamurthy R. Samson S. Bajaj M. (2011) Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity 19: 2310–2315.
80. Taylor K. Gurney K. Han J. Pencek R. Walsh B. Trautmann M. (2011) Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocrine Disord 11: 1–9.
81. Thong K. Jose B. Sukumar N. Cull M. Mills A. Sathyapalan T. et al. (2011) Safety, efficacy and tolerability of exenatide in combination with insulin in the association of British clinical diabetologists nationwide exenatide audit. Diabetes Obes Metab 13: 703–710.
82. Toft-Nielsen M. Madsbad S. Holst J. (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22: 1137–1143.
83. Wu J. Xu X. Zhu J. Ding B. Du T. Gao G. et al. (2011) Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther 13: 143–148.
84. Wysham C. Bergenstal R. Malloy J. Yan P. Walsh B. Malone J. et al. (2011) DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 28: 705–714.
85. Yang W. Chen L. Ji Q. Liu X. Ma J. Tandon N. et al. (2011) Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea, and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab 13: 81–88.
86. Yuan G. Song W. Huang Y. Guo X. Gao Y. (2012) Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study. Chin Med J 125: 2677–2681.
87. Zinman B. Hoogwerf B. Garcia S. Milton D. Gioconia J. Kim D. et al. (2007) The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 146: 477–485.
88. Zinman B. Gerich J. Buse J. Lewin A. Schwartz S. Raskin P. et al. (2009) Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32:1224–1230.